{"category": "ham", "to_address": "<ip-health@lists.essential.org>", "from_address": "\"Sean Flynn\" <sflynn@wcl.american.edu>", "subject": "[Ip-health] Malaysia data exclusivity", "body": "This is a multi-part message in MIME format.\n--\n[ Picked text/plain from multipart/alternative ]\nNew Straits Times\n\nFTA: Malaysia imposes terms on data exclusivity for US pharmaceuticals\n\n\n\n\n\nBy : BERNAMA\n\n\n\nPETALING JAYA, THURS:\n\nMalaysia has set some conditions in agreeing to the U.S. request for\ndata exclusivity (DE) for new pharmaceutical products in the bilateral\nfree trade agreement (FTA) negotiations, Health Minister Datuk Seri Dr\nChua Soi Lek said today.\n\n\n\nAmong the conditions: DE is for a five-year period effective from the\ntime a product obtains a DE from its country of origin, and it can only\nbe granted by Malaysia*s National Pharmaceutical Control Bureau (NPCB).\n\n\n\n*The U.S. wants DE for five years for pharmaceutical products and three\nyears for new clinical information,* he said.\n\n\n\n*The Malaysian government has adopted a stand, approved by the Cabinet\nlast year, that for new products the DE should only be for five years\nand should be given at the same date as at the country of origin.\n\n_______________________________________________\nIp-health mailing list\nIp-health@lists.essential.org\nhttp://lists.essential.org/mailman/listinfo/ip-health\n\n"}